786 related articles for article (PubMed ID: 19244125)
1. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Gobert M; Treilleux I; Bendriss-Vermare N; Bachelot T; Goddard-Leon S; Arfi V; Biota C; Doffin AC; Durand I; Olive D; Perez S; Pasqual N; Faure C; Ray-Coquard I; Puisieux A; Caux C; Blay JY; Ménétrier-Caux C
Cancer Res; 2009 Mar; 69(5):2000-9. PubMed ID: 19244125
[TBL] [Abstract][Full Text] [Related]
2. FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration.
Freier CP; Kuhn C; Endres S; Mayr D; Friese K; Jeschke U; Anz D
Anticancer Res; 2016 Jun; 36(6):3139-45. PubMed ID: 27272839
[TBL] [Abstract][Full Text] [Related]
3. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.
Iellem A; Mariani M; Lang R; Recalde H; Panina-Bordignon P; Sinigaglia F; D'Ambrosio D
J Exp Med; 2001 Sep; 194(6):847-53. PubMed ID: 11560999
[TBL] [Abstract][Full Text] [Related]
4. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
5. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
6. Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer.
Li YQ; Liu FF; Zhang XM; Guo XJ; Ren MJ; Fu L
PLoS One; 2013; 8(10):e76379. PubMed ID: 24124553
[TBL] [Abstract][Full Text] [Related]
7. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an antihuman CCR4 mAb (KM2760).
Kurose K; Ohue Y; Sato E; Yamauchi A; Eikawa S; Isobe M; Nishio Y; Uenaka A; Oka M; Nakayama E
J Thorac Oncol; 2015 Jan; 10(1):74-83. PubMed ID: 25325779
[TBL] [Abstract][Full Text] [Related]
8. Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma.
Klarquist J; Tobin K; Farhangi Oskuei P; Henning SW; Fernandez MF; Dellacecca ER; Navarro FC; Eby JM; Chatterjee S; Mehrotra S; Clark JI; Le Poole IC
Cancer Res; 2016 Nov; 76(21):6230-6240. PubMed ID: 27634754
[TBL] [Abstract][Full Text] [Related]
9. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
[TBL] [Abstract][Full Text] [Related]
10. Frequency, suppressive capacity, recruitment and induction mechanisms of regulatory T cells in sinonasal squamous cell carcinoma and nasal inverted papilloma.
Lou H; Fang J; Li P; Zhou W; Wang Y; Fan E; Li Y; Wang H; Liu Z; Xiao L; Wang C; Zhang L
PLoS One; 2015; 10(5):e0126463. PubMed ID: 26020249
[TBL] [Abstract][Full Text] [Related]
11. FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer.
Sarkar T; Dhar S; Chakraborty D; Pati S; Bose S; Panda AK; Basak U; Chakraborty S; Mukherjee S; Guin A; Jana K; Sarkar DK; Sa G
Front Immunol; 2022; 13():740588. PubMed ID: 35222362
[TBL] [Abstract][Full Text] [Related]
12. Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma.
Enarsson K; Lundgren A; Kindlund B; Hermansson M; Roncador G; Banham AH; Lundin BS; Quiding-Järbrink M
Clin Immunol; 2006 Dec; 121(3):358-68. PubMed ID: 16934529
[TBL] [Abstract][Full Text] [Related]
13. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
14. Lower numbers of FoxP3 and CCR4 co-expressing cells in an elevated subpopulation of CD4+CD25high regulatory T cells from Wegener's granulomatosis.
Klapa S; Mueller A; Csernok E; Fagin U; Klenerman P; Holl-Ulrich K; Gross WL; Lamprecht P
Clin Exp Rheumatol; 2010; 28(1 Suppl 57):72-80. PubMed ID: 20412707
[TBL] [Abstract][Full Text] [Related]
15. CCL1 is a major regulatory T cell attracting factor in human breast cancer.
Kuehnemuth B; Piseddu I; Wiedemann GM; Lauseker M; Kuhn C; Hofmann S; Schmoeckel E; Endres S; Mayr D; Jeschke U; Anz D
BMC Cancer; 2018 Dec; 18(1):1278. PubMed ID: 30572845
[TBL] [Abstract][Full Text] [Related]
16. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors.
Hirahara K; Liu L; Clark RA; Yamanaka K; Fuhlbrigge RC; Kupper TS
J Immunol; 2006 Oct; 177(7):4488-94. PubMed ID: 16982885
[TBL] [Abstract][Full Text] [Related]
17. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
Vocanson M; Rozieres A; Hennino A; Poyet G; Gaillard V; Renaudineau S; Achachi A; Benetiere J; Kaiserlian D; Dubois B; Nicolas JF
J Allergy Clin Immunol; 2010 Aug; 126(2):280-9, 289.e1-7. PubMed ID: 20624644
[TBL] [Abstract][Full Text] [Related]
18. Differences in tumor regulatory T-cell localization and activation status impact patient outcome.
Ménétrier-Caux C; Gobert M; Caux C
Cancer Res; 2009 Oct; 69(20):7895-8. PubMed ID: 19808962
[TBL] [Abstract][Full Text] [Related]
19. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
20. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.
Strauss L; Bergmann C; Szczepanski MJ; Lang S; Kirkwood JM; Whiteside TL
J Immunol; 2008 Mar; 180(5):2967-80. PubMed ID: 18292519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
